BACKGROUND: Although ongoing cohort studies offer a unique opportunity to apply existing information collected prospectively to further the scientific understanding of Parkinson's disease (PD), they typically have limited information for clinical diagnosis. METHODS: We used combinations of self-report, International Classification of Diseases - 9th edition codes and antiparkinsonian medications to identify PD in the Cardiovascular Health Study. To determine whether the expected inverse association between smoking and PD is evident using our outcome definitions, we assessed baseline smoking characteristics for various definitions of PD. RESULTS: We identified 60 cases with prevalent PD (1.0%; 95% confidence interval, CI = 0.8-1.3%) and 154 with incident PD by year 14. Clear associations were observed for current smokers (odds ratio, OR = 0.50; 95% CI = 0.26-0.95) and for those who smoked ≥50 pack-years (OR = 0.53; 95% CI = 0.29-0.96). Estimates for smoking were similar when ≥2 data sources were required. Estimates for self-report alone were attenuated towards null. CONCLUSIONS: Using multiple data sources to identify PD represents an alternative method of outcome identification in a cohort that would otherwise not be possible for PD research. Ongoing cohort studies can provide settings in which rapid replication and explorations of new hypotheses for PD are possible.
BACKGROUND: Although ongoing cohort studies offer a unique opportunity to apply existing information collected prospectively to further the scientific understanding of Parkinson's disease (PD), they typically have limited information for clinical diagnosis. METHODS: We used combinations of self-report, International Classification of Diseases - 9th edition codes and antiparkinsonian medications to identify PD in the Cardiovascular Health Study. To determine whether the expected inverse association between smoking and PD is evident using our outcome definitions, we assessed baseline smoking characteristics for various definitions of PD. RESULTS: We identified 60 cases with prevalent PD (1.0%; 95% confidence interval, CI = 0.8-1.3%) and 154 with incident PD by year 14. Clear associations were observed for current smokers (odds ratio, OR = 0.50; 95% CI = 0.26-0.95) and for those who smoked ≥50 pack-years (OR = 0.53; 95% CI = 0.29-0.96). Estimates for smoking were similar when ≥2 data sources were required. Estimates for self-report alone were attenuated towards null. CONCLUSIONS: Using multiple data sources to identify PD represents an alternative method of outcome identification in a cohort that would otherwise not be possible for PD research. Ongoing cohort studies can provide settings in which rapid replication and explorations of new hypotheses for PD are possible.
Authors: Sonja von Campenhausen; Bernhard Bornschein; Regina Wick; Kai Bötzel; Cristina Sampaio; Werner Poewe; Wolfgang Oertel; Uwe Siebert; Karin Berger; Richard Dodel Journal: Eur Neuropsychopharmacol Date: 2005-08 Impact factor: 4.600
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: D E Bild; A Fitzpatrick; L P Fried; N D Wong; M N Haan; M Lyles; E Bovill; J F Polak; R Schulz Journal: J Am Geriatr Soc Date: 1993-10 Impact factor: 5.562
Authors: M C de Rijk; M M Breteler; G A Graveland; A Ott; D E Grobbee; F G van der Meché; A Hofman Journal: Neurology Date: 1995-12 Impact factor: 9.910
Authors: D W Anderson; W A Rocca; M C de Rijk; F Grigoletto; M O Melcon; M M Breteler; D M Maraganore Journal: Mov Disord Date: 1998-07 Impact factor: 10.338
Authors: S Jain; T G Ton; R M Boudreau; M Yang; E L Thacker; S Studenski; W T Longstreth; E S Strotmeyer; A B Newman Journal: Neuroepidemiology Date: 2011-06-16 Impact factor: 3.282
Authors: Thanh G N Ton; Mary Lou Biggs; Diane Comer; Lesley Curtis; Shu-Ching Hu; Evan L Thacker; Susan Searles Nielsen; Joseph A Delaney; Douglas Landsittel; William T Longstreth; Harvey Checkoway; Samay Jain Journal: Pharmacoepidemiol Drug Saf Date: 2013-12-13 Impact factor: 2.890
Authors: Thanh G N Ton; Samay Jain; Mary L Biggs; Evan L Thacker; Elsa S Strotmeyer; Robert Boudreau; Anne B Newman; W T Longstreth; Harvey Checkoway Journal: Parkinsonism Relat Disord Date: 2011-11-26 Impact factor: 4.891
Authors: Samay Jain; Thanh G Ton; Subashan Perera; Yan Zheng; Phyllis K Stein; Evan Thacker; Elsa S Strotmeyer; Anne B Newman; Will T Longstreth Journal: Mov Disord Date: 2012-06-14 Impact factor: 10.338
Authors: Andrea L Rosso; Stephanie A Studenski; W T Longstreth; Jennifer S Brach; Robert M Boudreau; Caterina Rosano Journal: J Gerontol A Biol Sci Med Sci Date: 2017-09-01 Impact factor: 6.053
Authors: Mike A Nalls; Nathan Pankratz; Christina M Lill; Chuong B Do; Dena G Hernandez; Mohamad Saad; Anita L DeStefano; Eleanna Kara; Jose Bras; Manu Sharma; Claudia Schulte; Margaux F Keller; Sampath Arepalli; Christopher Letson; Connor Edsall; Hreinn Stefansson; Xinmin Liu; Hannah Pliner; Joseph H Lee; Rong Cheng; M Arfan Ikram; John P A Ioannidis; Georgios M Hadjigeorgiou; Joshua C Bis; Maria Martinez; Joel S Perlmutter; Alison Goate; Karen Marder; Brian Fiske; Margaret Sutherland; Georgia Xiromerisiou; Richard H Myers; Lorraine N Clark; Kari Stefansson; John A Hardy; Peter Heutink; Honglei Chen; Nicholas W Wood; Henry Houlden; Haydeh Payami; Alexis Brice; William K Scott; Thomas Gasser; Lars Bertram; Nicholas Eriksson; Tatiana Foroud; Andrew B Singleton Journal: Nat Genet Date: 2014-07-27 Impact factor: 38.330